Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Common Equity (2022 - 2025)

Historic Common Equity for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $301.6 million.

  • Centessa Pharmaceuticals' Common Equity fell 3958.09% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 3958.09%. This contributed to the annual value of $401.5 million for FY2024, which is 6997.05% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Common Equity stood at $301.6 million, which was down 3958.09% from $344.9 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Common Equity's 5-year high stood at $499.1 million during Q3 2024, with a 5-year trough of $215.2 million in Q1 2024.
  • Its 4-year average for Common Equity is $340.7 million, with a median of $336.2 million in 2022.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Common Equity skyrocketed by 9242.72% in 2024 and then crashed by 3958.09% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Common Equity (Quarter) stood at $336.2 million in 2022, then decreased by 29.72% to $236.2 million in 2023, then skyrocketed by 69.97% to $401.5 million in 2024, then fell by 24.9% to $301.6 million in 2025.
  • Its Common Equity was $301.6 million in Q3 2025, compared to $344.9 million in Q2 2025 and $386.2 million in Q1 2025.